Cannabinoids have been proposed for numerous neurodegenerative disorders. As a matter of fact, scientists employed by the US government filed a patent in 2001 for Cannabinoids as antioxidants and neuroprotectants, citing their potential for treating Alzheimer’s disease among others.
As you gaze upon these words, dear reader, a horde of alien marauders are ransacking all corners of the globe, chewing through the latest pharmaceutical defenses and leaving behind a gruesome trail of dead and weakened victims. According to a recent report by the World Health Organization (WHO), ferocious tribes of bacteria, parasites, viruses and fungi are on the rampage, and some are proving virtually invincible to the so-called “last resort” antibiotics.
It’s no secret that many cancer patients are using cannabis to help manage pain, fatigue, nausea, and other side effects of chemotherapy. Less well known is the fact that extensive preclinical research shows that plant cannabinoids — most notably,
How often have we heard, “More research is needed,” from those who would prefer to see no change in policies that should be informed by science? From climate denial to cannabis prohibition, the demand for absolute scientific certainty is a call for inaction.
It begs the question: When is there “enough” research?
Pain from inflammation can and will likely affect all adults at some point in their lives, and for some, become chronic conditions that interfere with a normal quality of life.